PRABHAT ARYA
Professor and Head, Dr Reddy's Institute of Life Sciences
Professor and Head
Organic and Medicinal Chemistry Program
http://www.prabhatarya.org
http://www.prabhatarya.org/pdf/Prabhat_Arya_Brief_Resume.pdfhttp://www.prabhatarya.org/biography.html
https://in.linkedin.com/pub/prabhat-arya/18/922/694
https://www.facebook.com/prabhat.arya.5817
Tel: (+91) (40) 6657 1513
Mobile (India): 91 9676984001
E mail: prabhata@drils.org , prabhat.arya@outlook.com
Prabhat Arya grew-up on the University of Delhi campus where he received his education (BSc Hons, MSc, MPhil, PhD, 1974-85). Following post-doctoral tenures (1985-89) with Professors Robert Corriu (Univ of Montpellier, France), Ian Paterson, FRS (Cambridge Univ) and Bill Chan (McGill Univ), he then joined the National Research Council of Canada, Ottawa and quickly climbed the ranks, and, worked with this organization for nearly 20 years. Later, he accepted a challenge to help the newly created institute, Ontario Institute for Cancer Research (OICR), to establish the Medicinal Chemistry Program. His long-standing quest to establish a Translational Chemical Biology Program that can stand at the international level, finally brought him to India in July 2009.
He started his India academic journey at the Institute of Life Sciences (later, renamed as the Dr. Reddy’s Institute of Life Sciences), located on the beautiful University of Hyderabad campus.
With an objective to building a novel chemical toolbox having small molecules that are more close to bioactive natural products, his team develops novel synthesis methods. Here the general goals are to develop methods that allow to access small molecules having some of the privileged sub-units of bioactive natural products and can be classified in the category of hybrid natural products. These compounds, in general, are having sufficient complexity to be easily workable in the drug discovery arena.
In particular, his team is building a toolbox having a diverse set of natural product-inspired macrocyclic compounds. Some of the key sections of bioactive natural products that his team is working on include: eribulin, rapamycin/FK506, epothilone, radicicol and salinomycin etc. Through working in a close partnership with several biomedical researchers, this toolbox is then thoroughly subjected to a wide variety of cell-based and zebrafish assays in a hunt for modulators of Protein-Protein Interactions (PPIs) and signaling pathways.
Over the years, his team has written several authoritative articles on the need to strengthen the advanced organic chemistry efforts for producing natural product-inspired chemical probes to explore their utilization in the signaling biology arena. To date, he has published 90 peer reviewed research articles, presented 130 invited talks and trained more than 55 post-doctoral fellows and several graduate and undergraduate students. During his tenure in Canada, he has served at various national and international committees dealing with grants and for developing science policies and has won several awards.
Prior to his move to India, He was also an Adjunct Professor with Chemistry Dept, University of Ottawa, Biochemistry Dept, McGill University, Affiliate Investigator, Ottawa Hospital Research Institute (OHRI) and Member, Ottawa Institute of Systems Biology.
He enjoys spending time with his students, other team members, and, loves sharing his vision and research plans in India. Often, he can be seen cycling on adventurous Indian roads and is having a lot of fun while testing his on and off road skills. He is also keen on promoting the bicycle culture and the need to do a regular exercise to stay on top of the India hectic life!
ABOUT DRILS
The Dr. Reddy's Institute of Life Sciences was conceived in the context of globalization, to foster research competence in India and to bridge the divide between academic research and the pharmaceutical & biotechnology industries.
The institute was incorporated as a non-profit entity under Section 25 of the Indian companies act, facilitating operational autonomy. Construction of the DRILS building comprising 44 labs and an administrative block and spanning ~130,000 sq.ft. in area, began in 2004 and was completed in January 2007.
The institute was inaugurated as a public-private partnership research institute on 29th January 2007, a culmination of the efforts and initiative of the Andhra Pradesh state government, Dr. Reddy's laboratories and the University of Hyderabad. The institute is located in the southeast corner of the campus of the University, one of the largest and greenest campuses in India.
Prabhat Arya, Professor and Head, Dr Reddy's Institute of Life Sciences
With an objective to moving
beyond the traditional chemical space and to building a toolbox with
small molecules that are more close to bioactive natural products, Dr
Arya’s team is working in this area for nearly two decades. These
compounds can be broadly defined as natural product-inspired and hybrid
natural products.
Over the years, his team has written several leading articles on the need to strengthen the advanced organic chemistry efforts to producing next generation small molecules to undertake challenging biological targets that are related to protein-protein interactions (PPIs) and, signaling pathways, in general.
Dr Arya has trained more than 50 post-doctoral fellows, several graduate and undergraduate students on this topic and delivered 140 lectures at various scientific meetings and research institutions. During his academic tenure in Canada, he served on various NIH and CIHR and NCIC (Canada) grant panels and worked in the committees that were assigned the task of establishing large scale chemical biology research programs within US and Canada.
Prior to making an adventurous move to India in July 2009, Dr Arya was a Research Officer (at various levels) at the National Research Council of Canada (NRCC) for nearly 20 years and had a brief stint at the Ontario Institute of Cancer Research help building the medicinal chemistry program. In addition, he was an Adjunct Professor at Biochemistry, McGill University, Chemistry and Biochemistry, University of Ottawa and Ottawa Health Research Institute (OHRI).
Over the years, his team has written several leading articles on the need to strengthen the advanced organic chemistry efforts to producing next generation small molecules to undertake challenging biological targets that are related to protein-protein interactions (PPIs) and, signaling pathways, in general.
Dr Arya has trained more than 50 post-doctoral fellows, several graduate and undergraduate students on this topic and delivered 140 lectures at various scientific meetings and research institutions. During his academic tenure in Canada, he served on various NIH and CIHR and NCIC (Canada) grant panels and worked in the committees that were assigned the task of establishing large scale chemical biology research programs within US and Canada.
Prior to making an adventurous move to India in July 2009, Dr Arya was a Research Officer (at various levels) at the National Research Council of Canada (NRCC) for nearly 20 years and had a brief stint at the Ontario Institute of Cancer Research help building the medicinal chemistry program. In addition, he was an Adjunct Professor at Biochemistry, McGill University, Chemistry and Biochemistry, University of Ottawa and Ottawa Health Research Institute (OHRI).
Experience
Founder and President
SignMod Pharmaceuticals
SignMod
Pharmaceuticals Inc. is an Indian drug discovery company focused on the
synthesis of natural product-inspired (NPI) small molecules which
interrupt protein-protein interactions (PPI) and modulate intracellular
signaling pathways. This class of molecules is the next wave of
marketable pharmaceutical therapies for conditions of high unmet needs
such as cancer, neurodegeneration, inflammation, diabetes/metabolic
disorders, infections and cardiovascular disorders. SignMod has
unparalleled synthetic organic chemistry technology with the ability to
produce high bioactivity small molecule libraries currently inaccessible
to big pharma.
It is well recognized that numerous disease families including cancer, stroke, immune deficiency, neurodegeneration and diabetes involve intracellular signaling pathways that are integrated via multiple, dynamic protein-protein interactions. Disruption of these interactions using small molecules promises to create tremendous opportunities for developing new therapeutic approaches for treating these disease families.
The company proposes to utilize highly specialized, unique capabilities in high throughput, diversity-oriented synthesis (DOS) in building a highly functionalized bicyclic to polycyclic and macrocyclic “natural product-inspired” small molecule toolbox. SignMod toolbox is unique, filled with compounds that occupy uncrowded chemical space due to their 3-Dimensional (3-D) natural product-inspired architectures, and they demonstrate superior hit rates (compounds with biological activity) versus conventional combinatorial libraries.
For further information on SignMod, visit our website: www.signmodpharma.com
It is well recognized that numerous disease families including cancer, stroke, immune deficiency, neurodegeneration and diabetes involve intracellular signaling pathways that are integrated via multiple, dynamic protein-protein interactions. Disruption of these interactions using small molecules promises to create tremendous opportunities for developing new therapeutic approaches for treating these disease families.
The company proposes to utilize highly specialized, unique capabilities in high throughput, diversity-oriented synthesis (DOS) in building a highly functionalized bicyclic to polycyclic and macrocyclic “natural product-inspired” small molecule toolbox. SignMod toolbox is unique, filled with compounds that occupy uncrowded chemical space due to their 3-Dimensional (3-D) natural product-inspired architectures, and they demonstrate superior hit rates (compounds with biological activity) versus conventional combinatorial libraries.
For further information on SignMod, visit our website: www.signmodpharma.com
Professor
Dr. Reddy's Institute of Life Sciences
My
long-standing quest to establish a chemical biology program in India
recently brought me back to my roots. I am thoroughly enjoying the
challenges of establishing this program at the Dr. Reddy's Institute of
Life Sciences, located on the University of Hyderabad campus.
With the objective of exploring new chemical space, my research aims to develop novel methods leading to building a natural product-inspired chemical toolbox. Small molecules from my group are then subjected to a wide variety of evaluation programs in a hunt for chemical modulators of protein-protein interaction-based signaling pathways related to cancer, metabolic disorders, infectious diseases and neurological disorders.
Over the years, we have written several authoritative articles on the need to strengthen the advanced organic chemistry efforts for producing natural product-inspired chemical probes to explore their utilization in the signaling biology arena.
For further detailed information, see our website: www.prabhatarya.org
With the objective of exploring new chemical space, my research aims to develop novel methods leading to building a natural product-inspired chemical toolbox. Small molecules from my group are then subjected to a wide variety of evaluation programs in a hunt for chemical modulators of protein-protein interaction-based signaling pathways related to cancer, metabolic disorders, infectious diseases and neurological disorders.
Over the years, we have written several authoritative articles on the need to strengthen the advanced organic chemistry efforts for producing natural product-inspired chemical probes to explore their utilization in the signaling biology arena.
For further detailed information, see our website: www.prabhatarya.org
Visting Scientist, Medicinal Chemistry Program
OICR
See this article:
http://oicr.on.ca/news/portal-news/dr-prabhat-arya-joins-medicinal-chemistry-program-term-visiting-scientist
http://oicr.on.ca/news/portal-news/dr-prabhat-arya-joins-medicinal-chemistry-program-term-visiting-scientist
Senior Research Officer, Steacie Institute for Molecular Sciences (SIMS)
National Research Council Canada
Associate Research Officer, Steacie Institute for Molecular Sciences (SIMS)
National Research Council Canada
Research Associate and then Assist Research Officer, Steacie Institute for Molecular Sciences (SIMS)
National Research Council Canada
Education
McGill University
Postdoctoral Fellow, Organic Synthetic Chemistry
Supervisor: Professor T. H. (Bill) Chan
Cambridge University
Postdoctoral Fellow, Organic Synthetic Chemistry
Supervisor: Professor Ian Paterson, FRS
Université Montpellier I
Maître de Conférence, Organic Chemistry
Supervisor: Professor Robert Corriu
National Chemical Laboratory
Research Associate, Natural Products Synthesis
Supervisor: Dr. A. V. Rama Rao
Delhi University
Doctor of Philosophy (PhD), Natural Products Synthesis
Supervisor: Professor A. C. Jain, FNA
Delhi University
Master of Philosophy (M.Phil.), Natural Products Synthesis
Supervisor: Professor A. C. Jain, FNA
STUDENTS
: Madhu Aeluri
: GVKBio Hyderabad
:
Synthesis of Natural product-inspired Macrocyclic Architectures and Hybrid Latrunculins.
PhD degree awarded, University of Hyderabad, Dec 2014.
: GVKBio Hyderabad
:
Synthesis of Natural product-inspired Macrocyclic Architectures and Hybrid Latrunculins.
PhD degree awarded, University of Hyderabad, Dec 2014.
: Srinivas Chamakuri
: Going to Join Professor Damian Young, Baylor College of Medicine, USA (June 2015)
: Synthesis of Amino-indoline Based Macrocycles and Treprostinil Inspired Hybrid Compounds.
PhD degree awarded, University of Hyderabad, Jan 2015.
: Going to Join Professor Damian Young, Baylor College of Medicine, USA (June 2015)
: Synthesis of Amino-indoline Based Macrocycles and Treprostinil Inspired Hybrid Compounds.
PhD degree awarded, University of Hyderabad, Jan 2015.
: Ravikumar Jimmidi
: GVKBio Hyderabad
:
A Divergent Approach to Benzofuran-inspired, Macrocycles and Eribulin Fragment-based Hybrid Compounds.
PhD degree awarded, University of Hyderabad, Feb 2015.
: GVKBio Hyderabad
:
A Divergent Approach to Benzofuran-inspired, Macrocycles and Eribulin Fragment-based Hybrid Compounds.
PhD degree awarded, University of Hyderabad, Feb 2015.
: Shiva Krishna Reddy Guduru
: Going to Join Professor Damian Young, Baylor College of Medicine, USA (July 2015)
: A Divergent Approach to Tetrahydroquinoline-Based Macrocycles and Rapamycin Fragment-Derived Hybrid Molecules.
PhD degree awarded, University of Hyderabad, March 2015.
: Going to Join Professor Damian Young, Baylor College of Medicine, USA (July 2015)
: A Divergent Approach to Tetrahydroquinoline-Based Macrocycles and Rapamycin Fragment-Derived Hybrid Molecules.
PhD degree awarded, University of Hyderabad, March 2015.
: Bhanudas Dasari
: Waiting for PhD thesis defence
:
Synthesis of Carbohydrate-based Macrocycles and Epothilone Fragment-derived Hybrid Molecules
PhD thesis submitted, University of Hyderabad, Dec 2014.
: Waiting for PhD thesis defence
:
Synthesis of Carbohydrate-based Macrocycles and Epothilone Fragment-derived Hybrid Molecules
PhD thesis submitted, University of Hyderabad, Dec 2014.
Ongoing PhD Students
: Srinivas Jogula
: Jan 2011
:
1. C-Glyco-based Macrocyclic Diversity (published in Eur. J. Org. Chem. 2014).
2. Stereoselective Synthesis of Ansamycin-based Hybrid Macrocycles.
: Jan 2011
:
1. C-Glyco-based Macrocyclic Diversity (published in Eur. J. Org. Chem. 2014).
2. Stereoselective Synthesis of Ansamycin-based Hybrid Macrocycles.
: Saidulu Konda
: Jan 2011
:
Stereoselective Synthesis of Western Furan Ring Fragment and Related Macrocyclic Compounds.
: Jan 2011
:
Stereoselective Synthesis of Western Furan Ring Fragment and Related Macrocyclic Compounds.
: Mahender Khatravath
: Jan 2011
:
Stereoselective Synthesis of the Sub-structures of Eribulin and Derived Macrocycles
: Jan 2011
:
Stereoselective Synthesis of the Sub-structures of Eribulin and Derived Macrocycles
: Naveen Kumar Mallurwar
: Jan 2011
:
Stereoselective Synthesis of Fragments of Eribulin and Derived Hybrid Macrocycles
: Jan 2011
:
Stereoselective Synthesis of Fragments of Eribulin and Derived Hybrid Macrocycles
: Jagan Gaddam
: Jan 2011
:
Stereoselective Synthesis of Neopeltolide Inspired Macrocyclic Compounds
: Jan 2011
:
Stereoselective Synthesis of Neopeltolide Inspired Macrocyclic Compounds
Past Group Members- Post-doctoral Fellows and Technical Officers
- Ms. U. Wronska, 1993-94, Canadian Patent Office, Ottawa
- Dr. Sho-Nong Wang, 1995, Sussex Research Labs, Ottawa
- Mr. Guy Boisvert, 1993-95, Technical Officer, Waters
- Mr. Sylvain Dion, 1996-97, Technical Officer, CHUL, Quebec City
- Dr. Suoding Cao, 1996, GlycoDesign, Toronto
- Dr. George Shimizu, 1996, Professor, Dept of Chem, Univ of Calgary
- Dr. Francois Maltais, 1996-97, Vertex Pharmaceuticals, USA
- Dr. Johanne Roby, 1997-98, CEGEP Teacher, Sherbrooke
- Dr. Robert Ben, 1996-98, Professor, Dept of Chem, Ottawa
- Dr. Huiping Qin, 1997-99, Software Eng, Sprint USA
- Dr. Kristina Kutterer, 1997-99, Wyeth Ayerst, NY, USA
- Dr. N. Venugopal Rao, 1998-00, Johnson Matthey Pharmaceuticals, USA
- Dr. Angela Barkley, 1998-01, Johnson Matthey Pharmaceuticals, USA
- Dr. Wei He, 1999-00, Naeja Pharmaceuticals, Alberta
- Dr. Yifa Zhou, 2000-01, Chiron Cooperation, Singapore
- Dr. Gautam Panda, 2000-01, Research Scientist, CDRI, Lucknow, India
- Dr. Karla Randell, 2000-01, Canadian Patent Office, Ottawa
- Dr. Myung-Gi Baek, 1999-01, BioMira, Edmonton, Alberta
- Dr. Doug Chou, 2000-02, Cardiome Pharma, Vancouver
- Dr. Bugga Sarma, 2000-02, SaiAdvantium Laboratories Ltd, India
- Dr. Suzanne Hof, 2000-02, Patent Law Company, Ottawa
- Dr. Zai-Xin Chen, 2001-02, Jiangsu Yabang Pharma, China
- Dr. Reni Joseph, 2001-03, MDS Pharma, Montreal (moved to USA)
- Dr. Patricia Durieux, 2002-03, Syngenta Crop Protection AG, Switzerland
- Dr. Samuel Couve-Bonnaire, 2002-03, Professor, Rouen, France
- Dr. Chang-Qing Wei, 2001-03, PainCeptor Pharma, Ottawa
- Dr. Majid Rastegar, 2002-04, PDF, Carleton University (presently with Health Canada)
- Dr. Rohtash Kumar, 2003-04, Research Scientist, Pharmaceutical Company, Alberta
- Dr. Nallareddy Babu, 2002-04, Research Scientist, Naeja Pharmaceuticals, Edmonton
- Ms. Sophie Quevillon, 2003-04, Research Scientist, Health Canada
- Dr. Zhonghong Gan, 2002-04, Research Scientist, Sussex Research Labs, Ottawa
- Ms. Maya Sharma, 2003-05, PhD Student, Dept of Chem, University of Manitoba
- Mr. Shahriar Khadem, 2001-05, Research Scientist, Health Canada, Ottawa
- Dr. Utpal Sharma, Research Scientist, 2003-05, Naeja Pharmaceuticals, Edmonton
- Dr. P. Thirupathi Reddy, 2003-06, Research Scientist, Pharmaceutical Company, Canada
- Dr. Ayub Reayi, 2004-06, Canadian Patent Office, Ottawa
- Dr. Deo Ntirampebura, 2005-06, PainCeptor Pharma, Ottawa
- Dr. Stuti Srivastava, 2004-06, Research Scientist, Pharmaceutical Company, India
- Dr. Ravi Naga Prasad, 2005-07, Research Scientist, Pharmaceutical Company, India
- Mr. Michael L. Barnes, 1996-2007, SIMS, NRC
- Dr. Michael Prakesch, 2004-07, Research Scientist, OICR Toronto
- Jean-Louis Brochu, 2005-08, Research Scientist, Pharmaceutical Company, Canada
- Dr. Rajamohan R. Poondra, 2006-08, Senior Research Scientist, Institute of Life Sciences (ILS), Hyderabad, India
- Dr. Ramdas Borhade, 2008-2009, Research Scientist, Pharmaceutical Company, India
- Dr. Nandyala Reddy, 2008-09, Post-Doctoral Fellow, McGill University
- Dr Sreedhar Pamu, 2008-09, Post-Doctoral Fellow, McGill University
- Dr. Lakshindra Chetia, 2008-09, Post-Doctoral Fellow, USA
- Dr. Chinmoy Pramanik, 2008-09, Post-Doctoral Fellow, USA
- Dr. Maragani Satyanarayana, 2008-09, Post-Doctoral Fellow, USA
- Dr. Niranjan Kumar, 2007-09, Post-Doctoral Fellow, USA
- Dr. Jyoti Prokash Nandy, 2004-09, Health Canada, Ottawa
- Ms. Lam Pham, 2007-09
- Rajnikanth, Research Trainee, 2011-12
- Buddipally Ramesh Reddy, Research Trainee, 2011-13
Past Group Members- Graduate Students
- Sophie Quevillon, Dept of Chem, Univ of Ottawa (Aug 2003), MS Thesis: Toward the Diversity-Oriented Synthesis of Indoline-based Polycyclic Derivatives.
- Kamani Ilangasinghe, Dept of Chem, Univ of Ottawa (Jan 2005), PhD Thesis: Stereocontrolled Diversity-Oriented Synthesis of 2H-Benzopyran-based Natural Product-like Polycyclic Derivatives.
- Jean-Louis Brochu, Dept of Chem, Univ of Ottawa (Oct 2008), MS Thesis: A Modular Tandem Michael or Aza Michael Approach to Obtain Indoline Alkaloid-like Polycyclic Architectures.
- Shahriar Khadem, Dept of Chem, Univ of Ottawa (May 2010), PhD Thesis: The Development of Stereocontrolled Methods to Obtain a Diverse Set of Tetrahydroquinoline-based, Natural Product-Inspired Compounds.
- Lam Pham, Dept of Biochemistry, Microbiology and Immunology, Univ of Ottawa (June 2010), MS Thesis: Natural Product-Inspired Chemical Modulators of Protein-Protein Interactions: The Pursuit of Three Lead Compounds.
- Madhu Aeluri, PhD thesis awarded (December 2014), University of Hyderabad. Thesis title: Synthesis of Natural product-inspired Macrocyclic Architectures and Hybrid Latrunculins. Joined as a scientist, GVKBio Hyderabad (one year assignment)
- Srinivas Chamakuri, PhD thesis awarded (January 2015), University of Hyderabad Thesis title: Synthesis of Amino-indoline Based Macrocycles and Treprostinil Inspired Hybrid Compounds.
- Ravi Kumar Jimmidi, PhD thesis awarded (Feb 2015), University of Hyderabad. Thesis title: A Divergent Approach to Benzofuran-inspired, Macrocycles and Eribulin Fragment-based Hybrid Compounds. Joined as a scientist, GVKBio Hyderabad (one year assignment)
- Shiva Krishna Reddy Guduru, PhD thesis submitted (Mar 2015), University of Hyderabad Thesis title: A Divergent Approach to Tetrahydroquinoline-Based Macrocycles and Rapamycin Fragment-Derived Hybrid Molecules.
- Bhanudas Dasari, PhD thesis submitted (Dec 2014), University of Hyderabad Thesis title: Synthesis of Carbohydrate-based Macrocycles and Epothilone Fragment-derived Hybrid Molecules.
Past Undergraduate Students
- Mario Rios, Dept of Chem, Univ of Ottawa (2000-01), Hons Thesis, A novel approach to chiral, polycyclic ring derivatives from D-galactose.
- Benoit Seguin, Dept of Chem, Univ of Ottawa (2000-01), Hons Thesis, Toward the synthesis of dihydroindole-derived natural product-like compounds.
- Karim Mekhail, Dept of Chem, Univ of Ottawa (2001-02), Hons Thesis, Toward enantioselective synthesis of highly functionalized eight-membered ring natural product-like derivatives.
- Paul Czechura, Dept of Chem, Univ of Ottawa (2001-02), Hons Thesis, Towards an enantioselective approach to indole alkaloid-like polycyclic derivatives.
- Mathieu Parisien, Dept of Chem, Univ of Ottawa (2002-03), Hons Thesis- A synthetic approach to indoline-derived polycyclic derivatives having a β-amino acid functionality.
- Marc Lafrance, Dept of Chem, Univ of Ottawa (2002-03), Hons Thesis- Synthesis of benzofuran-derived natural product-like tricyclic derivative.
- Louis-Charles Campeau, Dept of Chem, Univ of Ottawa (2002-03), Hons Thesis- Tetrahydroquinoline-derived β-amino acids as novel scaffolds for diversity-oriented synthesis.
- Daisy Laforce, Dept of Chem, Univ of Ottawa (2002-03), Hons Thesis- Towards the synthesis of tetrahydroquinoline-based polycyclic derivatives with medium size rings.
- Charles Roy, Dept of Chem, Univ of Ottawa (2003-04), Hons Thesis- Towards the synthesis of novel macrocyclic glycosamino acids.
- Juzer Kakal, Dept of Biochem, Univ of Ottawa (2003-04), Hons Thesis- Towards the synthesis of medium size ring derivatives from carbohydrates.
- Hilda Antony, Dept of Chem, Univ of Ottawa (2003-04), Hons Thesis- Tetrahydroaminoquinoline-derived β-amino acid and β- amino alcohol as novel scaffolds.
- Jean-Louis Brochu, Dept of Chem, Univ of Ottawa (2003-04), Hons Thesis- A synthetic approach to indoline-derived polycyclic derivatives.
- Kassandra Lepack, Dept Chem and Pharmaceutical Sciences, Univ of Ottawa, 2007-08, Hons Thesis- Natural product-inspired chemical modulators of Bcl-2 family.
- Monica Wirz, Dept Chem and Pharmaceutical Sciences, Univ of Ottawa, 2007-08, Hons Thesis- The development of a novel cycloaddition approach leading to benzofuran-derived polycyclic architectures.
- Sheila Michel, Dept Chem and Pharmaceutical Sciences, Univ of Ottawa, 2007-08, Hons Thesis- Novel chemical probes of Bcl-2 and Mcl-1 for developing cell death modulators.
- Asna Choudhry, Biochem Dept, Univ of Ottawa, 2007-08, Hons Thesis – Natural product-inspired chemical modulators of focal adhesion kinase (FAK) pathways.
February 17-19, 2014 • HICC, Hyderabad, IndiaProf. Prvabhat Arya
Head, Organic & Medicinal
Chemistry Program,
Dr. Reddy's Institute vof Life Sciences
Chemistry Program,
Dr. Reddy's Institute vof Life Sciences
The challenges of small molecules as drug candidates continue to attract the debate of global bio-pharma R&D industry. Late stage failures and narrowing pipeline has empowered small and medium discovery R&D companies with opportunities. Scope for innovation is very high, considering the inefficiencies and success rates. So drug discovery significantly influence the performance of bio-pharma R&D. Drug Discovery conference of BioAsia identifies India as an opportunity for global bio-pharma R&D, while investigating key trends of the industry for the benefit of participants. BioAsia identifies drug discovery as an important discipline as an ongoing opportunity to track scientific developments and promote collaborations.
////////
No comments:
Post a Comment